• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Basit Chaudhry on the Importance of Taking Into Account Differences Among OCM Practices

Video

Under the Oncology Care Model (OCM), there's a wide range of practice sizes, creating challenges for evaluation, said Basit Chaudhry, MD, PhD, founder of Tuple Health.

Under the Oncology Care Model (OCM), there's a wide range of practice sizes, creating challenges for evaluation, said Basit Chaudhry, MD, PhD, founder of Tuple Health.

Transcript

Why is it important for OCM evaluation to take into consideration differences among participating practices?

One of the things that’s very different about OCM, in part because of the selection criteria for entering the model, it was really oriented around practices in the community or outpatient setting. What this has done is the participants inside of OCM, there’s often a scale order of difference in how large they are. So, this is a kind of interesting thing. In other CMMI [Center for Medicare and Medicaid Innovation] models, you don’t have this kind of massive difference in scale. There’s, I believe, a practice that’s a 1-physician practice in OCM and there’s a 300-physician practice in OCM. This creates real challenges on the evaluation, because if you’re trying to essentially match practices as comparisons, it becomes very difficult because of the very skewed distribution.

The evaluation of this model is also particularly important because due to the complexity of cancer care on the model itself, there have been a number of methodologic changes that have been made along the way. So, in a way, it’s a moving target over what OCM performance is, so the evaluators I think, have a very important job to think about how do we really assess what the impact of this payment model has been. That’s especially important in this model, and it’s key to all CMMI models, but it’s especially important in OCM. There’s a lot of decisions that will need to be made on how the evaluation will be done, so it will be interesting to see how that works.

Related Videos
Screenshot of Susan Wescott, RPh, MBA
Screenshot of an interview with Adam Colborn, JD
Screenshot of an interview with James Chambers, PhD
Screenshot of an interview with Megan Ehret, PharmD
Interview screenshot with Megan Ehret, PharmD
Screenshot of an interview with Susan Wescott, RPh, MBA
Screenshot of an interview with Nadine Barrett, PhD
Female doctor in coat with stethoscope on blue background - Pixel-Shot - stock.adobe.com
Anna-Maria Hoffmann-Vold, MD, PhD, a senior consultant and leader of inflammatory and fibrotic research area at Oslo University Hospital
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.